Drugs / TBI 302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03908840 | Dec 2019 → Dec 2020 | hepatocellular carcinoma | Evolve Biologics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI 302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908840 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT03908840 ↗ |